Clinical trial NCT05159271: Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults
Official title: Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults: the EXSPRAY Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nasal Congestion
Lead sponsor: Larena SAS
Sponsor class: INDUSTRY
Collaborators: name: BioFortis
First posted: 2021-12-16
Enrollment: 144
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective is to evaluate the efficacy of Azéol Spray Nasal, taken two times a day, versus placebo on nasal congestion in subject with common cold.

Detailed description: This study is designed as a multicentric, randomized, double-blind, placebo-controlled with two-arm parallel groups clinical trial. 144 subjects presenting with early symptoms of common cold will be recruited for this study, according to the defined inclusion and exclusion criteria. The main objective is to evaluate the efficacy of Azéol Spray Nasal (Bifidobacterium breve LA 708, extract of cypres Cupressus sempervirens L., extract of Leguminosae Glycyrrhiza glabra L., glycerin and mannitol), taken two times a day, versus placebo on nasal congestion in subject with common cold.

Eligibility criteria: Inclusion Criteria:

I1. Subject aged between 18 and 65 years (limits included); I2. Subjects with early symptoms of common cold (onset less than or equal to 48 hours before inclusion upon subjects' declaration);

I3. Subjects with:

* A minimum nasal congestion score (blocked nose) of 2 (moderate) according to a 4-point scale (0 not present; 1 mild; 2 moderate; and 3 severe) assessed by Likert scale,
* Presenting a minimum of two common cold symptoms (runny nose, blocked nose, sore throat, and/or cough) at inclusion visit (V1) assessed with a score ≥ 1 according to a 4-point scale (0 not present; 1 mild; 2 moderate; and 3 severe) assessed by Likert,
* Minimum plugged nose (nasal congestion) score of 3 (≥ 3) assessed by WURSS-21;

I4. For women:

* Non menopausal with the same reliable contraception since at least 2 cycles before the beginning of the study and agreeing to keep it during the entire duration of the study (condom with spermicide gel, any oral contraceptive, intrauterine device, subcutaneous contraceptive implant, vaginal ring, surgical intervention (bilateral tubal ligation or ovariectomy or hysterectomy), ESSURE system),
* Menopausal without or with hormone replacement therapy; I5. Subject with good general and mental health according to the investigator opinion: no clinically significant and relevant abnormalities of medical history or physical examination; I6. Subject able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form; I7. Subject affiliated with a social security scheme; I8. Subject who agree to be registered on the volunteers in biomedical research file.

Exclusion Criteria:

E1. Subjects with nasal polyps/polyposis or nasal septum malformations or other nasal structural abnormalities that would compromise administration of the nasal spray (based on the declaration of the subjects); E2. Subjects with any other acute ear, nose, and throat and respiratory tract disease than the common cold (eg, tonsillitis, otitis, bronchitis) and chronic sinusitis or allergic rhinitis; E3. Subject suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, or other chronic respiratory trouble, etc.);

E4. Subject under:

* Concomitant treatment that might impair the trial results (eg, decongestants, local anesthetics, topical corticosteroids, saline solution) during the seven days prior to enrollment in the trial,
* Cough treatment or NSAID or any other treatment for the common cold during the seven days prior to enrollment in the trial,
* Any dietary supplement or probiotic; E5. Subjects with known or suspected hypersensitivity to the investigational device ingredients or to ingredients which could cause crossed allergia as cypress, peach or citrus fruit; E6. Subjects not fully vaccinated against SARS-CoV-2 virus; E7. Subjects positive for SARS-CoV-2 tested by rapid antigen test at V1; E8. Subjects with fever ≥ 38 °C; E9. Pregnant or lactating women or intending to become pregnant within the month ahead and during the whole study;

E10. Having a lifestyle deemed incompatible with the study according to the investigator as described below:

* Consuming more than 2 standard drinks of alcoholic daily or 14 weekly or not agreeing to keep his alcohol consumption habits unchanged throughout the study,
* Smoking more than five cigarettes daily or more than 60 mg of nicotine daily,
* Practicing high level of physical activity (defined as more than 10 hours of intense physical activity a week, walking excluded); E11. Subject taking part in another clinical trial or being in the exclusion period of a previous clinical trial; E12. Subject having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros; E13. Subject under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision; E14. Subject presenting a psychological or linguistic inability to sign the informed consent;

Primary outcomes:
measure: relief of nasal congestion at 2 days
timeFrame: 2 days
Secondary outcomes:
measure: relief of nasal congestion
timeFrame: 7 days
measure: Area Under the Curve for sick feeling score, global severity score, symptom score and for quality-of-life score
timeFrame: 7 days
measure: Area Under the Curve for common cold symptoms
timeFrame: 7 days
measure: Area Under the Curve for nine quality-of-life items
timeFrame: 7 days
measure: Area Under the Curve for the total nasal airway resistance to airflow
timeFrame: First day
measure: Time to onset of subjective relief nasal congestion from day 1
timeFrame: 7 days
measure: Time to onset of subjective relief symptoms from day 1
timeFrame: 7 days
measure: Subject's assessment of common cold feeling compared to the day before
timeFrame: 7 days
measure: Subjects' assessment of efficacy
timeFrame: 7 days
measure: Presence of secondary infections in the month after the D7
timeFrame: 1 month after D7
Other outcomes:
measure: Presence of cold viruses in nasal fluid samples
timeFrame: 3 days
measure: Safety endpoint
timeFrame: First day and 3 days
measure: Safety endpoint
timeFrame: 1 month after D7
Locations:
city: Dijon
country: France
facility: CEN Nutriment
city: Saint-Herblain
country: France
facility: Biofortis - Unité d'investigation clinique
Study officials:
References: